Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: 15th International Conference on Human Retroviruses: HTLV and Related Viruses

Open Access Meeting abstract

Prevalence of XMRV in blood donors, HTLV and HIV cohorts

Xiaoxing Qiu1*, Priscilla Swanson1, Ning Tang2, Gregor W Leckie2, Sushil Devare1, Gerald Schochetman1 and John Hackett1

Author Affiliations

1 Abbott Diagnostics, Infectious Diseases, Abbott Park, North Chicago, Illinois, 60064, USA

2 Abbott Molecular Inc., Des Plaines, IL, 60018, USA

For all author emails, please log on.

Retrovirology 2011, 8(Suppl 1):A222  doi:10.1186/1742-4690-8-S1-A222

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/8/S1/A222


Published:6 June 2011

© 2011 Qiu1 et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

PCR-based testing has been widely utilized to assess the prevalence of Xenotropic Murine Leukemia Virus-related Virus (XMRV) in prostate cancer and chronic fatigue syndrome patients. An alternative approach, screening for antibodies elicited by XMRV infection, represents a more desirable option for large-scale epidemiologic studies. In this study, blood donor and retrovirus-infected populations were screened for serologic evidence of XMRV infection.

Methods

Plasma from 1000 US blood donors, 100 HIV-1 infected Cameroonians, 486 HTLV-I infected Japanese, and 156 Japanese HTLV-uninfected controls were screened for antibodies to XMRV gp70 and p15E using recombinant-based chemiluminescence immunoassays (CMIAs). CMIA reactive samples were further evaluated by Western Blot (WB) and real-time RT-PCR for XMRV pol and env sequences.

Results

Of US donors, 0.8% (8/1000) were CMIA reactive: 1 p15E and 3 of 7 gp70 reactive samples WB confirmed yielding a 0.4% seroreactive rate. No HIV-1 infected specimens were reactive. Of the Japanese samples, 1/156 uninfected (0.6%) and 20/486 HTLV-infected samples (4.1%) had detectable p15E antibodies by CMIA and WB. Eight additional HTLV-infected samples were gp70 reactive; 4 of 486 (0.8%) were gp70 reactive in WB. No XMRV pol or env sequences were detected in the seroreactives.

Conclusions

XMRV seroprevalence ranged from 0 - 0.6% in US blood donors, HIV-1 infected and HTLV uninfected subjects. Notably, 4.1% of Japanese HTLV-I infected individuals were p15E reactive. Inspection of sequence homology between HTLV and XMRV revealed a high level of conservation within the immunodominant region of HTLV gp21 suggesting increased seroreactivity is due to cross-reactive antibodies.